Pancreatic Adenocarcinoma
Conditions
Keywords
Pancreatic adenocarcinoma
Brief summary
Purpose of this study is to understand the clinical feasibility of duodenal spectroscopy to adenocarcinoma patients.
Detailed description
Pancreatic cancer (PC) is the most lethal of all major cancers with a five year survival rate of 5 %. While stage I and II tumors leads to an improvement in survival, almost all PCs are currently diagnosed at more advanced non-resectable stages since minimally invasive technique which is capable of screening early-stage PC does not exist. Serum CA19-9 is not recommended as a screening technique because of its low sensitivity and specificity. Imaging modalities such as MRI, CT, EUS and ERCP are more accurate but are not appropriate screening tools due to their high cost, discomfort and complications. Therefore, there is a strong demand for a screening tool with high sensitivity and specificity which is highly acceptable for the patient. The investigators would like to look at the spectroscopy technique for pancreatic cancer diagnosis via an upper endoscopy. A definite diagnosis of the patient is made with histology, cytology or imaging diagnosis. Therefore this study can be positioned as a feasibility study.
Interventions
OTHERSpectroscopy device
Spectrum data are collected using spectroscopy device via an instrumental channel of endoscope. Then spectrum data is analyzed. Numerical features (spectral slope and width of spectrum) are used for statistical analysis.
Sponsors
M.D. Anderson Cancer Center
Catholic University of the Sacred Heart
Erasme University Hospital
Olympus Corporation
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Common inclusion criterion * Age is 18 years or older. * Informed consent was obtained. * Inclusion criterion for normal cohort * An upper GI endoscopy is scheduled to check upper abdominal symptoms. * No findings of pancreatic disorder as documented by CT or MRI or EUS * Inclusion criterion for PC suspicious cohort \* A EUS or ERCP is scheduled to suspected pancreatic disorder.
Exclusion criteria
* Common exclusion criterion * Severe cardiac disease * Severe respiratory disease * Bleeding disorders * Pregnancy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The spectral data of the normal cohort and UICC stage II pancreatic ductal adenocarcinoma cohort | 1 year | To clarify that there is the statistically-significant difference between two cohorts. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The sensitivity and specificity to detect UICC stage II pancreatic ductal adenocarcinoma among all participants. | 1 year | A receiver operating characteristic (ROC) is evaluated. A cut-off is then chosen from this ROC curve to maximize both sensitivity and specificity. |
Countries
Belgium, Italy, United States
Outcome results
None listed